Amid the ongoing controversy over Yoga guru Baba Ramdev's company Patanjali Ayurveda introducing "cure" for coronavirus infection, Rajasthan government on Wednesday clarified that this drug cannot be not used as a medicine in the state without the permission of the Ministry of AYUSH.
Neither has anyone applied to the state government nor has the state government given any permission in this regard, State Health Minister Raghu Sharma said.
He said according to the gazette notification issued by the Government of India in April this year, under the Drugs and Cosmetic Act 1940 and 1945, no ayurvedic medicine can sold as medicine for corona infection during COVID-19 pandemic without the approval of Union Ministry of AYUSH.
Strict action will be taken against the seller as per the rules in case of sale of any drug as a medicine to treat the coronavirus infection, the minister added.
Patanjali Ayurveda, while presenting ''Coronil'' medicine on Tuesday had claimed that it has found a cure for coronavirus infection.
Sharma said compliance of the guidelines of the Union Ministry of Health, Union Ministry of AYUSH and ICMR is being ensured in the treatment of coronavirus infection in the state.
The health minister said no human clinical test of a drug can be done without the permission of the state government and action will be taken against those who mislead the common people by doing ''clinical trials'' without permission.
Referring to the various guidelines of the central government and other regulatory bodies, Sharma said without their compliance, action will be taken against the publicity and sale of any such means to treat the infection.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)